Abstract: Disclosed herein are compounds of formula (1):
wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6) alkyl, amido, amino or phenyl; R2 is (C4-6)cycloalkyl; R3 is t-butyl or (C5-6) cycloalkyl and R4 is (C4-6)cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease.
Abstract: Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.
Type:
Grant
Filed:
December 12, 2000
Date of Patent:
October 21, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Jinhua J. Song, Nathan K. Yee, Suresh R. Kapadia
Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and salmeterol, processes for their production and their use in the therapy of respiratory ailments.
Type:
Grant
Filed:
February 14, 2002
Date of Patent:
October 7, 2003
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Karl-Heinz Bozung, Michel Pairet, Richard Reichl, Alexander Walland
Abstract: Bicyclic heterocycles of general formula
wherein:
Ra to Rd, A to C and X are as defined herein, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.
Type:
Grant
Filed:
March 23, 2001
Date of Patent:
September 30, 2003
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Frank Himmelsbach, Elke Langkopf, Birgit Jung, Stefan Blech, Flavio Solca
Abstract: A compound of Formula Ia
wherein:
R1 and R2, which are the same or different, are CF3; halogen; CN; branched or unbranched C1-8 alkyl; branched or unbranched C1-8 alkenyl; C3-8 cycloalkyl optionally substituted with OH, CN, or methoxy; C1-8 alkoxy; C1-4 alkyloxyalkyl; C1-8 alkylthio; C1-4 alkylthioalkyl; C1-8 dialkylamino; C1-4 dialkylaminoalkyl; CO2R4 where R4 is C1-4 alkyl or C1-4 alkenyl optionally substituted with carbocyclyl or heterocyclyl; or aryl or heterocyclyl connected to the imidazole in any position that makes a stable bond wherein the aryl or the heterocyclyl thereof is optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4;
L is —NHC(O)—; —NHC(O)O—; —NHC(O)C(O)—; —NHC(S)—; —NH—; —NHC(O)NH—; —NHC(S)NH—; —NHCH2—; —NHCH(R5)—, wherein R5 is H, CN, C1-6 alkyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinyl
Type:
Grant
Filed:
March 23, 2000
Date of Patent:
September 30, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
Type:
Grant
Filed:
April 21, 2000
Date of Patent:
September 2, 2003
Assignees:
Boehringer Ingelheim Pharma KG, Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Raymond A. Firestone, Wolfgang J. Rettig, Martin Lenter, Stefan Peters, Pilar Garin-Chesa, Juergen Mack, Dietmar Leipert, John E. Park, Leila A. Telan
Abstract: Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
September 2, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Jinhua J. Song, Nathan K. Yee, Suresh R. Kapadia
Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases.
Type:
Grant
Filed:
October 24, 2001
Date of Patent:
August 19, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
Abstract: Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.
Type:
Grant
Filed:
April 13, 2001
Date of Patent:
August 19, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Steffen Breitfelder, Pier F. Cirillo, John R. Regan
Abstract: Disclosed is a novel method of producing heteroaryl amines of the formula(I):
wherein X, Y and Z are described herein, the heteroarylamines are useful in the production of heteroaryl ureas which are key component in pharmaceutically active compounds possessing a heteroaryl urea group.
Type:
Grant
Filed:
July 11, 2001
Date of Patent:
August 5, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Nathan Yee, Suresh R. Kapadia, Jinhua J. Song
Abstract: Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
July 15, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Jinhua J. Song, Nathan K. Yee, Suresh R. Kapadia
Abstract: Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
July 8, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Jinhua J. Song, Nathan K. Yee, Suresh R. Kapadia
Abstract: Disclosed are novel processes and novel intermediate compounds for preparing aryl- and heteroaryl-substituted urea compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein. The product compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.
Type:
Grant
Filed:
July 6, 2000
Date of Patent:
June 24, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Abstract: A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-but l-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments.
Type:
Grant
Filed:
July 11, 2001
Date of Patent:
May 20, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Michael Cappola, George W. Gereg, Susan Way
Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
February 25, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Pier Francesco Cirillo, Roger Dinallo, John Robinson Regan, Paul S. Riska, Alan David Swinamer, Zhulin Tan, Brian Andrew Walter
Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
Type:
Grant
Filed:
March 14, 2001
Date of Patent:
February 25, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
January 14, 2003
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Abstract: The invention relates to a new process for preparing optically active dihydropyrones, new intermediate products which may be obtained by this synthesis, and their use as starting compounds in the preparation of pharmaceutically active compounds.
Abstract: Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
Type:
Grant
Filed:
November 16, 2000
Date of Patent:
December 10, 2002
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Steffen Breitfelder, Pier F. Cirillo, Ming-Hong Hao, Eugene R. Hickey, Rajiv Sharma, Sanxing Sun, Hidenori Takahashi
Abstract: Disclosed are aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein, and intermediate compounds useful for making such compounds. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.
Also disclosed are processes of making compounds of the formula (I), their intermediates and processes of making such intermediates, including bis pyrazole-1H-pyrazole intermediates of the formula:
wherein Alk, Rx and Rz are described herein.
Type:
Grant
Filed:
February 5, 2002
Date of Patent:
December 10, 2002
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Suresh R. Kapadia, Jinhua J. Song, Nathan K. Yee